Tesamorelin 10mg – Research Peptide

Tesamorelin 10mg is supplied as a lyophilized research peptide intended strictly for laboratory and analytical applications. Tesamorelin is commonly evaluated in controlled research environments involving GHRH receptor (GHRHR) pathway studies and downstream signaling investigations.

Research Context

Tesamorelin is studied in laboratory settings for its interaction with growth hormone–releasing hormone (GHRH) signaling pathways. Ongoing research examines receptor-binding behavior, signaling characteristics, and downstream pathway activity in standardized experimental models.

Product Specifications

• Compound: Tesamorelin
• Quantity: 10mg per vial
• Format: Lyophilized powder
• Appearance: White to off-white
• Storage: Store in a cool, dry environment prior to reconstitution
• Documentation: Third-party analytical documentation available

Commonly Evaluated in Complementary Research Protocols

• CJC-1295 / Ipamorelin – studied in growth hormone pathway research models
• Sermorelin – evaluated in GHRH-related signaling research
• NAD+ – commonly assessed in cellular energy pathway studies

Frequently Asked Questions

Why does the vial label differ from the Bandit Research branding?

Select products may be supplied in standardized laboratory vials used across extended inventory formats. Regardless of label variation, all products offered through Bandit Research are sourced and quality-verified under the same internal standards and documentation requirements.

Certificate of Analysis (COA)

Third-party analytical documentation for the batch used in this product format is available below. Batch-level testing is conducted for identity and analytical verification.

Why Bandit Research

• Competitive laboratory pricing structure
• Transparent documentation
• Discreet U.S.-based fulfillment
• Focused exclusively on research inventory

Research Use Only. This product is intended strictly for laboratory research purposes. Not for human consumption, medical use, or veterinary application.